Cardiovascular Risk clinical trials

Explore recruiting cardiovascular risk clinical trials.

Recruiting cardiovascular risk studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cardiovascular Risk trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

Latvia, Italy, Estonia, Czechia, Finland, Netherlands +16 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of Allopurinol on the Risk of Cardiovascular Events in Patients With High and Very High Cardiovascular Risk, Including the Presence of Long-COVID Syndrome.

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

Combined impact of cardiovascular polypill treatment and a specific nurse education program on adherence to therapy in patients with ACS: a randomized study

Spain

Therapeutic use (Phase IV) EU CTIS Study details

StAtins in Frail oldEr patients with ischemic Stroke or Transient ischemic attack

Netherlands

Therapeutic use (Phase IV) EU CTIS Study details

REPLACE - A multi-centre, randomised, double-blinded, placebo controlled 16-weeks study to compare the effect of hydrocortisone and placebo in patients with Giant Cell Arteritis (GCA)/ Polymyalgia Rheumatica (PMR) with patient-reported symptoms of adrenal insufficiency after cessation of glucocorticoid treatment.

Denmark

Therapeutic use (Phase IV) EU CTIS Study details

TheRapeutic StrAtegies for Obstructive SleeP Apnea in Older Adults with OverweigHt or Obesity: A RandomizEd Clinical TriaL (RAPHAEL study)

Spain

Therapeutic use (Phase IV) EU CTIS Study details

Cardiovascular Risk trials by city

Cardiovascular Risk in Toronto Cardiovascular Risk in Vancouver Cardiovascular Risk in Montreal Cardiovascular Risk in Calgary Cardiovascular Risk in Edmonton Cardiovascular Risk in Ottawa Cardiovascular Risk in Winnipeg Cardiovascular Risk in Quebec City Cardiovascular Risk in Hamilton Cardiovascular Risk in Kitchener Cardiovascular Risk in London Cardiovascular Risk in Halifax Cardiovascular Risk in New York Cardiovascular Risk in Los Angeles Cardiovascular Risk in Chicago Cardiovascular Risk in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease